Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) FCF Margin (2016 - 2025)

Historic FCF Margin for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to 10.79%.

  • Niagen Bioscience's FCF Margin fell 27100.0% to 10.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.96%, marking a year-over-year increase of 125300.0%. This contributed to the annual value of 11.99% for FY2024, which is 36600.0% up from last year.
  • Latest data reveals that Niagen Bioscience reported FCF Margin of 10.79% as of Q3 2025, which was down 27100.0% from 3.53% recorded in Q2 2025.
  • Niagen Bioscience's FCF Margin's 5-year high stood at 29.23% during Q4 2024, with a 5-year trough of 46.1% in Q2 2021.
  • Its 5-year average for FCF Margin is 6.31%, with a median of 1.15% in 2024.
  • In the last 5 years, Niagen Bioscience's FCF Margin tumbled by -367200bps in 2021 and then surged by 538300bps in 2023.
  • Quarter analysis of 5 years shows Niagen Bioscience's FCF Margin stood at 27.85% in 2021, then surged by 91bps to 2.38% in 2022, then soared by 224bps to 2.96% in 2023, then soared by 887bps to 29.23% in 2024, then tumbled by -63bps to 10.79% in 2025.
  • Its FCF Margin was 10.79% in Q3 2025, compared to 3.53% in Q2 2025 and 25.81% in Q1 2025.